Cited by 946PARP inhibition in cancer therapyBRCA gene mutations in cancerOvarian cancer diagnosis and treatment

The DOI matches its Crossref record; 178 of the 180 references it cites were found in a registry or an index.

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

Open access

Konstantinopoulos, Panagiotis A., Ceccaldi, Raphael, Shapiro, Geoffrey I., D'Andrea, Alan D.·2015·Cancer Discovery

DOI 10.1158/2159-8290.cd-15-0714PMC PMC4631624

Open this paper in CoChat — free account

Abstract

Approximately 50% of epithelial ovarian cancers (EOC) exhibit defective DNA repair via homologous recombination (HR) due to genetic and epigenetic alterations of HR pathway genes. Defective HR is an important therapeutic target in EOC as exemplified by the efficacy of platinum analogues in this disease, as well as the advent of PARP inhibitors, which exhibit synthetic lethality when applied to HR-deficient cells. Here, we describe the genotypic and phenotypic characteristics of HR-deficient EOCs, discuss current and emerging approaches for targeting these tumors, and present challenges associated with these approaches, focusing on development and overcoming resistance. Significance: Defective DNA repair via HR is a pivotal vulnerability of EOC, particularly of the high-grade serous histologic subtype. Targeting defective HR offers the unique opportunity of exploiting molecular differences between tumor and normal cells, thereby inducing cancer-specific synthetic lethality; the promise and challenges of these approaches in ovarian cancer are discussed in this review. Cancer Discov; 5(11); 1137–54. ©2015 AACR.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-15-0714

Cites

178 of 178 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cancer statistics, 2015
Siegel, R. L., Miller, K. D., & Jemal, A. (2015) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21254 · Cited by 11,854
Cancer statistics, 2013
Siegel, R., Naishadham, D., & Jemal, A. (2013) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21166 · Cited by 11,825
Signatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
The resurgence of platinum-based cancer chemotherapy
Kèlland, L. R. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2167 · Cited by 4,733
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke‐Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,798
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B. N., Wenzel, L. B., Huang, H. Q., Baergen, R. N., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,626
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279

Show all 180 references

Sorted by citations

Items 701–800 of 946

PARP Inhibitor Sensitivity in Tumors Harboring Non-BRCA Homologous Recombination Gene Alterations: Current Evidence Across Ovarian, Breast, Prostate, and Pancreatic Cancers
Santos, E. S. D., Cicilini, A. L., Simões, M. F. E., Baz, M., Caputo, S. M., & Rouleau, É. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27156754 · Cited by 2
Phase 3 clinical trials evaluating poly(ADP-ribose) polymerase inhibition plus immunotherapy for first-line treatment of advanced ovarian cancer
Rimel, B. J., Pujade-Lauraine, É., Moore, K. N., Pfisterer, J., Han, S., Cibula, D., Reyners, A. K. L., Redondo, A., Papadimitriou, C., Eitan, R., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf270 · Cited by 2
A turning point in the fight against ovarian cancer?
Scambia, G., & Ferrandina, G. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30005-6 · Cited by 2
Novel agents to target treatment resistance in ovarian cancer
Washington, C. R., Richardson, D. L., Agyemang, A. F., Odunsi, K. O., & Moore, K. N. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819840-7.00008-x · Cited by 2
The Landscape of Personalized Medicine in Gynecologic Cancer
Foxall, M. E., & Arend, R. C. (2022) · Advances in Oncology · doi:10.1016/j.yao.2022.02.001 · Cited by 2
Frontline Management of Advanced Epithelial Ovarian Cancer: A Comprehensive Statement by the Africa Middle East Cancer Inter-group [AMCI]
Seoud, M., Ladjeroud, A., Jaafar, H., Mokhtar, M., Özyılkan, Ö., Alkhayyat, S. S., Dawood, S. S., Arık, Z., & Azim, H. A. (2022) · Current Women s Health Reviews · doi:10.2174/1573404819666221021091708 · Cited by 2
Multidisciplinary Care of a Large Brain Metastasis in a Patient with Hormone-Receptor-Positive Breast Cancer with Ataxia-Telangiectasia Mutation
Chelariu-Raicu, A., Piha-Paul, S. A., Chávez‐MacGregor, M., Johnson, J. M., Sawaya, R. A., McAleer, M. F., Nguyen, A., Hartnett, A., Tsimberidou, A. M., Meric‐Bernstam, F., et al. (2023) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-22-33 · Cited by 2
Clinical and molecular biomarkers predicting response to PARP inhibitors in ovarian cancer
Nozaki, T., Sakamoto, I., Kagami, K., Amemiya, K., Hirotsu, Y., Mochizuki, H., & Omata, M. (2024) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2024.35.e55 · Cited by 2
ceRNA Network and WGCNA Analyses of Differentially Expressed Genes in Cervical Cancer Tissues for Association with Survival of Patients
Luo, Y., Liu, Z., & Hu, X. (2024) · Reproductive Sciences · doi:10.1007/s43032-024-01477-z · Cited by 2
Identification of a False-positive Multiplex Ligationdependent Probe Amplification Result in BRCA1 Using a Copy Number Variation Algorithm Under Development for a Commercial Next-Generation Sequencing-based Homologous Recombination Deficiency Assay
Concolino, P., Paolis, E. D., Rinelli, M., Maneri, G., Brisighelli, F., Trozzi, R., Duranti, S., Giacò, L., Piane, M., Preziosi, A., et al. (2024) · Annals of Laboratory Medicine · doi:10.3343/alm.2024.0051 · Cited by 2
RAD51 recruitment but not replication fork stability associates with PARP inhibitor response in ovarian cancer patient-derived xenograft models
Talens, F., Teixeira, V., Kok, Y. P., Chen, M., Rosenberg, E. H., Debipersad, R. D., Duiker, E. W., van den Tempel, N., Janatová, M., Zemánková, P., et al. (2024) · NAR Cancer · doi:10.1093/narcan/zcae044 · Cited by 2
Facteurs prédictifs et biomarqueurs précoces de réponse aux inhibiteurs de checkpoint immunologiques (anti-PD-1, anti-PD-L1)
Colle, E., André, T., Lebbé, C., & Borg, C. (2016) · ONCOLOGIE · doi:10.1007/s10269-016-2664-y · Cited by 2
How to measure homologous recombination deficiency in ovarian cancer
Marchetti, C., & McNeish, I. A. (2017) · Cancer Breaking News · doi:10.19156/cbn.2017.0034 · Cited by 2
Disease Distribution at Presentation Impacts Benefit of IP Chemotherapy Among Patients with Advanced-Stage Ovarian Cancer
Manning‐Geist, B. L., Sullivan, M. W., Sarda, V., Gockley, A. A., Carmen, M. G. D., Matulonis, U. A., Growdon, W. B., Horowitz, N. S., Berkowitz, R. S., Clark, R. M., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-021-09746-w · Cited by 2
Quantifying Replication Stress in Ovarian Cancer Cells Using Single-Stranded DNA Immunofluorescence
Ramakrishnan, N., Haseljic, E., & Verma, P. (2023) · Journal of Visualized Experiments · doi:10.3791/64920 · Cited by 2
Disrupting prostate cancer research: Challenge accepted; report from the 2023 Coffey‐Holden Prostate Cancer Academy Meeting
Miyahira, A. K., Kamran, S. C., Jamaspishvili, T., Marshall, C. H., Maxwell, K. N., Parolia, A., Zorko, N. A., Pienta, K. J., & Soule, H. R. (2024) · The Prostate · doi:10.1002/pros.24721 · Cited by 2
Development of PARP Inhibitors for BRCA-Deficient Epithelial Ovarian Cancer
Parkes, E. E., McCabe, N., & KENNEDY, R. J. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-811785-9.00036-3 · Cited by 2
Rucaparib in the landscape of PARP inhibition in ovarian cancer
Colomba, É., Pautier, P., Pommeret, F., & Leary, A. F. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1607302 · Cited by 3
A tumor-infiltrating immune cells-related pseudogenes signature based on machine-learning predicts outcomes and immunotherapy responses in ovarian cancer
Zhang, Y., Guo, M., Wang, L., Weng, S., Xu, H., Ren, Y., Liu, L., Guo, C., Cheng, Q., Luo, P., et al. (2023) · Cellular Signalling · doi:10.1016/j.cellsig.2023.110879 · Cited by 2
A deep learning approach for improved detection of homologous recombination deficiency from shallow genomic profilesPreprint
Andre, G., Coletta, T., Pozzorini, C., Marques, A. C., Bieler, J., Kempfer, R., Chong, C., Saitta, A., Smith, E. W., Macheret, M., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.07.06.498851 · Cited by 2
Association of TP53 clonal hematopoiesis with indeterminate potential with the development of myeloid neoplasms after rucaparib treatment
Yoshida, R., & Nakamura, S. (2022) · Annals of Translational Medicine · doi:10.21037/atm-2022-65 · Cited by 2
Shedding Light on PARP Inhibitor Response through Functional Imaging
Liu, Y. L., & Zamarin, D. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-3711 · Cited by 2
Models of High-Grade Serous Ovarian CarcinomaPreprint
Pundel, O. J., & Neel, B. G. (2025) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041949 · Cited by 2
Rucaparib for the treatment of ovarian cancer
Cyriac, S. L., Karakasis, K., & Oza, A. M. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2018.1419129 · Cited by 1
Case report: Response to everolimus in a patient with platinum resistant, high grade serous ovarian carcinoma with biallelic TSC2 inactivation
Peterson, M. S., Kolin, D. L., & Konstantinopoulos, P. A. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1357980 · Cited by 1
Self-citation
Clinicopathological Significance of Defective DNA Mismatch Repair in Endometrial Carcinoma: A Single-Center Study From Bahrain
Hammad, M., Almahari, S. A., Umakanth, S., & Toorani, Z. A. (2024) · Cureus · doi:10.7759/cureus.67332 · Cited by 1
Dual Targeting of CX3CR1 and PARP in Models of High-Grade Serous Ovarian Carcinoma
Xie, J., & Barbolina, M. V. (2024) · Cancers · doi:10.3390/cancers16223728 · Cited by 1
Clonal evolution and molecular mechanisms of ovarian cancer: a comprehensive review
Nagasaka, K. (2024) · Academia oncology. · doi:10.20935/acadonco7484 · Cited by 1
Deciphering gene mutations in the efficacy and toxicity of antineoplastic drugs: an oncology pharmacist’s perspective
Jiang, Y., & Wen, G. A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1574010 · Cited by 1
Platinum free interval and clinical benefit of the second-line chemotherapy in recurrent uterine and ovarian carcinosarcoma: a retrospective cohort analysis
Berthet, J., Kime, A., Borghese, B., Percin, S. D., Gaudet-Chardonnet, A., Alexandre, J., & Beinse, G. (2025) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2025.36.e64 · Cited by 1
Combination of PARP Inhibitor and Antiangiogenic Therapy Following Disease Progression in Patients With Epithelial Ovarian Cancer Undergoing PARP Inhibitor Maintenance Therapy: A Real‐World Study
Zhang, N., Zheng, H., Gao, Y., Shu, T., Wang, H., & Cai, Y. (2025) · BJOG An International Journal of Obstetrics & Gynaecology · doi:10.1111/1471-0528.18179 · Cited by 1
S-1 plus oxaliplatin versus modified FOLFIRINOX for advanced pancreatic adenocarcinoma after gemcitabine plus nab-paclitaxel failure
Tang, H. J., Li, Z., You, T., Ying, J., Yuan, M., Cheng, Y., Wang, Y., Wu, H., & Bai, C. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251378698 · Cited by 1
Comprehensive assessment of homologous recombination deficiency via simultaneous methylation and mutation analysis in epithelial ovarian cancer: implications for PARP inhibitors efficacy
Lin, D., Wu, H., Li, N., Li, W., Song, Y., Xiong, Y., Yin, H., Fang, H., Chen, R., Yi, X., et al. (2025) · Biomarker Research · doi:10.1186/s40364-025-00843-6 · Cited by 1
Lactate Enhances Non-Homologous End Joining Repair and Chemoresistance Through Facilitating XRCC4–LIG4 Complex Assembly in Ovarian Cancer
Lu, J., Zhu, J., Zhang, H., Zhou, Z., Haoyuan, L., Zheng, C., Huang, X., Chen, S., Pan, C., Li, J., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13122949 · Cited by 1
Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Antitumor Immunity
Singh, D., Onyeagucha, B. C., Medina, D., Subbarayalu, P., Mojidra, R., Lv, D., Bhandari, M., Timilsina, S., Venkata, P. P., Huang, J. Y., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-25-0521 · Cited by 1
DNA damaging agents boost the transcription of endothelin A receptor in high-grade serous ovarian cancer
Román, C., Sestito, R., Caprara, V., Sacconi, A., Blandino, G., Bagnato, A., & Tocci, P. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03607-0 · Cited by 1
Emerging Therapeutic Synergies: Combining PD-1 Inhibitors With Poly-ADP-Ribose Polymerase (PARP) Inhibitors in the Treatment of Gynecologic Cancers
Azhar, M. S. M., Loh, Z., Mutamba, F. T., Algahiny, A., Yunusa, N. M., Paramasevon, S., & Almusarhed, M. (2025) · Cureus · doi:10.7759/cureus.99275 · Cited by 1
Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer
Salmon, C., Neves, R. P., Stoecklein, N. H., Liffers, S., Siveke, J. T., Kuhlmann, J. D., Wimberger, P., Buderath, P., Kimmig, R., & Kasimir‐Bauer, S. (2025) · Molecular Oncology · doi:10.1002/1878-0261.70193 · Cited by 1
APOBEC3B enhances the efficacy of PARP inhibitors in elimination of ovarian cancer stem cell
Rivera, M., Liu, L., Enlund, S., Lim, C.-E., Zhang, H., Yang, K., Šášik, R., Crews, L. A., Fisch, K. M., Eskander, R. N., et al. (2026) · Scientific Reports · doi:10.1038/s41598-026-35939-y · Cited by 1
Assessing the association between homologous recombination deficiency scores and treatment response in localized and metastatic prostate cancer
Zhu, Q., Shi, Y., Wang, T., Zheng, Q., Zhou, X., Tan, Z., Chen, J., Guo, J., Liu, H., Shen, P., et al. (2026) · The Journal of Pathology Clinical Research · doi:10.1002/2056-4538.70069 · Cited by 1
Recommandations pour la pratique clinique Nice/Saint-Paul-de-Vence 2024–2025 : prise en charge du cancer épithélial de l’ovaire de haut grade
Selle, F., Rodrigues, M. J., You, B., Gladieff, L., Bessard, A. C. H., Rouge, T. D. L. M., Fumet, J.-D., Saux, O. L., Colombo, P., Ferron, G., et al. (2026) · Bulletin du Cancer · doi:10.1016/j.bulcan.2025.12.004 · Cited by 1
The New Era of Intraperitoneal Carboplatin in Ovarian Cancer: From Biological Rationale to Clinical Implementation
Nagao, S., Fujikawa, A., Tanaka, Y., Tanioka, M., Imatani, R., Tani, Y., Sugihara, H., Okamoto, K., Matsuoka, H., Ida, N., et al. (2026) · Cancers · doi:10.3390/cancers18050764 · Cited by 1
RAD51-targeting small molecule degrader sensitizes BRCA-proficient prostate cancer cells to PARP inhibitors via synthetic lethality
Jian, Y., Gao, Y., Zhou, T., Xu, S., Wang, B., Fan, Y., Ma, J., Gao, Y., Liu, J., Ma, B., et al. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.03.029 · Cited by 1
HRD‐Driven Reprogramming of Macrophage Function and Spatial Architecture in High‐Grade Serous Ovarian Cancer
Lan, H., Xu, F., Li, L., Wei, X., & Li, M. (2026) · Genetics Research · doi:10.1155/genr/7364793 · Cited by 1
MuGNet: a graph-based framework for multi-tissue integration in computational pathology
Miccolis, F., Demarco, M., Ficarra, E., & Lovino, M. (2026) · PeerJ Computer Science · doi:10.7717/peerj-cs.3820 · Cited by 1
ROS-Induced DNA Damage Enhances Sensitivity to PARP Inhibition in HSC3 and SCC25 Head and Neck Squamous Cell Carcinoma Cell Lines
Pourianazar, N. T. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48070692 · Cited by 1
Efficacy of PARP Inhibitors in the Treatment of Ovarian Cancer: A Literature-Based Review
Goswami, V., Koyyala, V. P. B., Goyal, S., Sharma, M. R., Goel, V., Dhamne, N. A., Maheshwari, U., & Sharma, A. (2019) · Asian Journal of Oncology · doi:10.1055/s-0039-1700619 · Cited by 1
Chemotherapy in Gynaecological Cancers and Newer Developments
Tilby, M., Williams, S. V., & Pascoe, J. S. (2022) · Springer eBooks · doi:10.1007/978-3-030-94110-9_11 · Cited by 1
Epithelial tumor compartment- and adjacent stromal compartment-specific expression of PARP1 in different anatomical sites in patients with HGSOC
Berkel, Ç., & Çaçan, E. (2022) · Genome Instability & Disease · doi:10.1007/s42764-022-00075-0 · Cited by 1
Defektif Homolog Rekombinasyon DNA Tamiri ve PARP İnhibisyonu Arasındaki Sentetik Letal Etkileşim
Toy, Y., Gündoğdu, R., SEVER, A., & Erdoğan, M. K. (2022) · Iğdır Üniversitesi Fen Bilimleri Enstitüsü Dergisi · doi:10.21597/jist.1095366 · Cited by 1
Diagnosis and treatment of ovarian cancer in the light of modern molecular genetic achievements
Марсельевна, К. Э., Khusainova, R. I., & Minniakhmetov, I. R. (2023) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2023-22-5-118-133 · Cited by 1
Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
Levine, M. D., Wang, H., Sriram, B., Khan, A., Senter, L. A., McLaughlin, E. M., Bixel, K. L., Chambers, L., Cohn, D. E., Copeland, L. J., et al. (2024) · Gynecologic Oncology · doi:10.1016/j.ygyno.2023.12.008 · Cited by 1
Feasibility and cost-effectiveness of genetic counselling for all patients with newly diagnosed ovarian cancer: a single-centre retrospective study
Schlootz, S., Saner, F. A. M., Rabaglio, M., Imboden, S., & Wampfler, J. (2024) · Swiss Medical Weekly · doi:10.57187/s.3386 · Cited by 1
From Therapy to Cancer Prevention Using HRD Testing on Patients with High-grade Ovarian Cancer
Tibiletti, M. G., Carnevali, I. W., Facchi, S., Pensotti, V., Formenti, G., Sahnane, N., Libera, L., Ronchi, S., Volorio, S., Pierotti, M. A., et al. (2025) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-24-0474 · Cited by 1
Development of a prognosis model for PARP inhibitor therapies based on multiple genomic alterations associated with homologous recombination deficiency in ovarian cancer
Shu, T., Yang, F., Gao, L., Zhou, J., Zhang, C., Chen, Y., Zheng, H., & Li, J. (2025) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2025.101987 · Cited by 1
Psychophysical and social impact of risk-reducing salpingo-oophorectomy in China: a cross-sectional study
Ha, X., Feng, Z., Xia, J., Liu, Z., Wang, J., Zuo, K., Lin, Y., Chen, Y., Wen, H., & Wu, X. (2025) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2025.102135 · Cited by 1
Homologous Recombination and BRCA Genes in Ovarian Cancer
Liu, J. F., & Konstantinopoulos, P. A. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803741-6.00006-9 · Cited by 1
Self-citation
Olaparib as maintenance treatment in relapsed platinum-sensitive BRCA mutated ovarian cancer: real world experience in two Italian cancer Centers
Cecere, S. C., Lepori, S., Napoli, M. D., Pisano, C., Rossetti, S., Ventriglia, J., Paciolla, I., Maltese, G., Fontanella, C., Raspagliesi, F., et al. (2017) · Cancer Breaking News · doi:10.19156/cbn.2017.0036 · Cited by 1
How safe is rucaparib in ovarian cancer?
Cosgrove, C. M., & O’Malley, D. M. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1550067 · Cited by 1
Niraparib in the Treatment of Previously Treated Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Rimel, B. J., Dockery, L., Randall, L. M., & Moore, K. N. (2020) · Future Oncology · doi:10.2217/fon-2020-0538 · Cited by 1
The role of molecular tests for adjuvant and post-surgical treatment in gynaecological cancers
Wijaya, S. T., Ngoi, N. Y. L., & Tan, D. S. P. (2021) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2021.06.003 · Cited by 1
Variants of Uncertain Significances in Hereditary Breast and Ovarian Cancer
Yoshino, Y., & Chiba, N. (2021) · Springer eBooks · doi:10.1007/978-981-16-4521-1_4 · Cited by 1
Pharmacogenomics in solid cancers and hematologic malignancies: Improving personalized drug prescription
Maillard, M., Louveau, B., Vilquin, P., Goldwirt, L., Thomas, F., & Mourah, S. (2021) · Therapies · doi:10.1016/j.therap.2021.11.003 · Cited by 2
The Important Role of Poly ADP-Ribose Polymerase Inhibitor in Prostate Cancer
Joung, J. Y., & Kim, S. H. (2022) · Journal of Urologic Oncology · doi:10.22465/kjuo.2022.20.1.1 · Cited by 1
Recent Advances in Ovarian Cancer Treatment
Asai‐Sato, M. (2022) · Journal of Nihon University Medical Association · doi:10.4264/numa.81.1_23 · Cited by 1
Systematic Literature Review of Efficacy and Safety of First-Line Maintenance Therapy Trials in Advanced Ovarian Cancer
Guy, H., Hawkes, C., Walder, L., Malinowska, I. A., & Gupta, D. (2022) · Future Oncology · doi:10.2217/fon-2022-0578 · Cited by 1
The Significance of Radiotherapy in Ovarian Clear Cell Carcinoma: A Systematic Review and Meta-Analysis
Zhuang, Y., & Yang, H. (2023) · Cancer Control · doi:10.1177/10732748231179291 · Cited by 1
Cáncer de ovario epitelial seroso de alto grado, BRCA negativo, en dos mujeres de 18 años. Reporte de casos
Cortés-Esteban, P., Gómez-Ávalos, J., Millán-Aguilar, H. A., Adame-González, I., & Jasso-Sosa, V. (2023) · Gaceta Mexicana de Oncología · doi:10.24875/j.gamo.220000951 · Cited by 1
Mechanism and rational combinations with GP ‐2250, a novel oxathiazine derivative, in ovarian cancer
Kim, M. S., Glassman, D., Handley, K. F., Ahumada, A. L., Jennings, N. B., Bayraktar, E., Foster, K. I., Joseph, R., Lee, S., Coleman, R. L., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70031 · Cited by 1
Time to go functional! Determining tumors’ DNA repair capacityex vivo
Tumiati, M., Hietanen, S., & Kauppi, L. (2018) · Oncotarget · doi:10.18632/oncotarget.26419 · Cited by 1
Precision medicine in ovarian cancer: disparities and inequities in access to predictive biomarkers
Barberis, M. C. P., Colombo, N., & Cerana, N. (2024) · Pathologica · doi:10.32074/1591-951x-959 · Cited by 1
Repression of PRMT activities sensitize homologous recombination-proficient ovarian and breast cancer cells to PARP inhibitor treatmentPreprint
Zhang, Y., Xu, M., Yuan, J., Hu, Z., Jiang, J., Huang, J. S., Wang, B., Shen, J., Long, M., Fan, Y., et al. (2024) · eLife · doi:10.7554/elife.99225.1 · Cited by 1
On the predictability of progression-free survival in ovarian cancer from NanoString gene expression dataPreprint
Kleunen, L. B. V., Bowman, G. I., Stockman, S. E., Townsend, H. A., Barrios, L., Jordan, K. R., Wolsky, R. J., Behbakht, K., Sikora, M. J., Richer, J. K., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.22.719856 · Cited by 2
La génétique somatique des tumeurs solides, un incontournable à l’ère de la médecine de précision
Lehmann‐Che, J., Poirot, B., Boyer, J. C., & Evrard, A. (2017) · Therapies · doi:10.1016/j.therap.2016.09.009
Cyclin E1 as a therapeutic target in high grade serous ovarian cancer
Au‐Yeung, G. (2017) · Minerva Access (University of Melbourne)
Ovarian Cancer Genome and Molecular Experimental Sciences
Matsumura, N., & Konishi, I. (2017) · Comprehensive gynecology and obstetrics · doi:10.1007/978-981-10-4160-0_7
Synthetic Lethality: Achilles Heel in Select Patient Subpopulations
Teo, M. Y., & O'Reilly, E. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-58256-6_14
CLINICAL AND MORPHOLOGICAL FEATURES OF HEREDITARY OVARIAN CANCER
Kotiv, K. B., Gorodnova, T. V., Ivantsov, A. O., Iyevleva, A. G., Алексахина, С. Н., Manichas, G. M., Lisyanskaya, A. S., Salomatov, R. P., Shushaniia, M. S., Borodenko, M. V., et al. (2017) · Siberian Journal of Oncology · doi:10.21294/1814-4861-2017-16-6-31-40
Novel Systemic Treatments in High Grade Ovarian Cancer
Samani, A., Chan, C., & Krell, J. (2018) · InTech eBooks · doi:10.5772/intechopen.71583
Targeting vulnerabilities through inhibiting the valosin-containing protein (VCP/p97) in ovarian cancer
Bastola, P. (2018) · ProQuest Demo Repository
Deficyty BRCA1 i syntetyczna letalność w białaczkach; nie tylko mutacje mają znaczenie
Piwocka, K., Podszywalow‐Bartnicka, P., & Skórski, T. (2018) · Postępy Biochemii · doi:10.18388/pb.2018_124
Advances in the Treatment of Endometrial and Ovarian Cancer
Mutch, D. G. (2019) · touchREVIEWS in Oncology & Haematology · doi:10.17925/ohr.2019.15.1.23
Expressão de BRCA1 e BRCA2 por imuno-histoquímica e prognóstico no câncer de ovário: uma revisão sistemática e meta-análise
Teixeira, L. A. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2019.tde-04102019-111509
Novel biomarkers associated with histotype and clinical outcome in early-stage ovarian carcinoma
Engqvist, H. (2020) · Gothenburg University Publications Electronic Archive (Gothenburg University)
Lynch Syndrome-Associated Gynecological Malignancies
Yamagami, W., & Aoki, D. (2020) · Springer eBooks · doi:10.1007/978-981-15-6891-6_6
Practical aspects of treating relapsed BRCA-associated ovarian cancer
Rumyantse, A. A., & Tyulyandina, A. S. (2019) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2019-19-144-149
Transcriptome and interactome analyses identify the TP53 interacting gene RCCD1 as a candidate susceptibility gene at the 15p26.1 breast and ovarian cancer risk locusPreprint
Plummer, J., Dezem, F. S., Chen, S. S., Dhungana, S., Wali, D., Davis, B. D., Kanska, J. E., Safi, N., Seo, J.-H., Corona, R. I., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.09.29.319699
60-jährige Patientin mit fortgeschrittenem Ovarialkarzinom
Concin, N., & du Bois, A. (2020) · Der Gynäkologe · doi:10.1007/s00129-020-04657-5
Implication and clinical application of translational medicine in the management of common urologic cancers
Struss, W. J. (2020)
The development of drug resistance through reversion mutation in BRCA genes in ovarian cancer
Christie, E. L., Freimund, A. E., Fereday, S., Alsop, K., Hoang, T., Pishas, K. I., Au‐Yeung, G., Friedlander, M. L., & Bowtell, D. D. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819840-7.00013-3
Neoadjuvant chemotherapy for IIIC stage ovarian cancer - case report
Obuchowska, A., Standyło, A., Ozga, A., Wójcik, J., Obuchowska, K., & Skorupski, P. (2020) · Journal of Education Health and Sport · doi:10.12775/jehs.2020.10.09.009
The Effect of Metformin on DNA Damage, Proliferation and Apoptosis in High-Grade Serous Ovarian Cancer Cells
Ciparyte, A. (2020) · Työväentutkimus Vuosikirja
LCK Regulates Homologous Recombination DNA Repair Identifying a New Target for Sensitizing PARP Inhibitors in HR Proficient Ovarian CancerPreprint
Dey, G., Bharti, R., Braley, C., Alluri, R. K., Esakov, E. L., Crean-Tate, K., McCrae, K. R., Joehlin-Price, A. S., Rose, P. G., Lathia, J. D., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.03.433791
Ovarian Cancer: Towards Personalizing Ovarian Cancer Treatments Using Patient-Derived Organoids
Volpari, T., Hebner, J., Aiyar, R. S., & Martin, L. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820472-6.00080-3
Gynecological Cancer Prevention of the Modern Era
Asai‐Sato, M. (2021) · Journal of Nihon University Medical Association · doi:10.4264/numa.80.4_167
Genetic Alterations in Ovarian Cancer as Prognostic and Predictive Biomarkers of Therapy Response and Surgical Outcomes
Bairi, K. E., Jarroudi, O. A., & Afqir, S. (2021) · Springer eBooks · doi:10.1007/978-981-16-1873-4_4
An Introduction to the Current Management of Ovarian Cancer in the Era of Precision Oncology
Giunta, E. F., Pappalardo, A., Trapani, D., & Petrillo, A. (2021) · Springer eBooks · doi:10.1007/978-981-16-1873-4_2
Overcoming PARP Inhibitor and Platinum Resistance with WEE1 Inhibitors in Ovarian Cancer
Colombo, I. (2021) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2021.09.047
Testing for homologous recombination deficiency – does it provide new insights for the use of veliparib?
Ledermann, J. A. (2022) · Gynecologic Oncology · doi:10.1016/j.ygyno.2022.01.018
Hereditary gynecologic tumors and precision cancer medicine
Ogawa, C., Hirasawa, A., Ida, N., Nakamura, K., & Masuyama, H. (2022) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.15197

Authors: Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I., & D'Andrea, A. D.
Affiliations: Harvard University (US)
2Center for DNA Damage and Repair, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Corresponding author: Konstantinopoulos, Panagiotis A.
ORCID: Konstantinopoulos, Panagiotis A.
Shapiro, Geoffrey I.
Venue: Cancer Discovery
Publisher: American Association for Cancer Research (AACR)
Published: 2015-11-01
Volume: 5
Issue: 11
Pages: 1137-1154
ISSN: 2159-8274 (ISSN-L)
2159-8290
DOI: 10.1158/2159-8290.cd-15-0714
PMC: PMC4631624
OpenAlex: W2179105349
Cited by: 945
References: 180
Citations by year: 2026: 67 · 2025: 97 · 2024: 109 · 2023: 126 · 2022: 115 · 2021: 102 · 2020: 100 · 2019: 74 · 2018: 74 · 2017: 54 · 2016: 27
FWCI: 5.56
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Cancer Discovery (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA090687, UM1CA186709, P50CA168504)
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
Keywords: homologous recombination deficiency, epithelial ovarian cancer, DNA repair deficiency, PARP inhibitors, synthetic lethality, platinum analogues, high-grade serous ovarian cancer, drug resistance, targeted therapy
MeSH terms: Carcinoma, Ovarian Epithelial, Animals, Antineoplastic Combined Chemotherapy Protocols, Clinical Trials as Topic, DNA Repair, Female, Humans, Neoplasms, Glandular and Epithelial, Ovarian Neoplasms, Phenotype, Genetic Variation, Signal Transduction, Biomarkers, Gene Expression Regulation, Neoplastic, Treatment Outcome, Drug Resistance, Neoplasm, Molecular Targeted Therapy, Homologous Recombination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks